• Bayer, Haplogen ink R&D deal for pulmonary diseases fiercebiotech
    August 15, 2018
    Bayer and Evotec partner Haplogen will work to identify new treatments for pulmonary diseases including chronic obstructive pulmonary disease (COPD) under a multiyear drug discovery and development collaboration. 
PharmaSources Customer Service